Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02548455 · ClinicalTrials.gov registry record · NA
Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study
A NA study of Heart Failure, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 499
- Enrollment target
- 20
- Study locations
NCT02548455: Completed NA study of Heart Failure, sponsored by Abbott Medical Devices.
NCT02548455 is a NA study of Heart Failure that has completed, run by Abbott Medical Devices. The registered enrollment target is 499 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02548455, a NA study of Heart Failure, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 499 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary intent of this study is to assess the safety of the model 1457Q Quartet LV lead at 3 months in a patient population indicated for cardiac resynchronization therapy.
Primary Outcome
A complication is defined as a Serious Adverse Device Effect related to the Quartet 1457Q lead. A Serious Adverse Device Effect is an event related to the use of a medical device that led to death, a life-threatening illness or injury, a permanent impairment to a body structure or a body function, an in-patient or prolonged hospitalization, medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body, a malignant tumor OR fe
Conditions Studied
Interventions
- DEVICE Quartet 1457Q LV Lead
Study Locations (20)
California
- Scripps Health - La Jolla
- Premier Cardiology, Inc. - Newport Beach
- Stanford University Hospital - Stanford
Florida
- Munroe Regional Medical Center - Ocala
- Tallahassee Research Institute - Tallahassee
Georgia
- Emory University Hospital - Atlanta
- North Georgia Heart Foundation - Gainesville
Kentucky
- Central Baptist Hospital - Lexington
- One Health Cardiology - Owensboro
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
Alabama
- Heart Center Research - Huntsville
Arizona
- Arizona Arrhythmia Research Center - Phoenix
Arkansas
- Cardiology Associates of Northeast Arkansas - Jonesboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 499 participants |
| Start Date | 2015-10-27 |
| Est. Completion | 2017-03-21 |
| Phase | NA |
What the finished NCT02548455 record still lists
NCT02548455 is an interventional study that assigns participants to a tested intervention. The registered 499 participants enrollment target is mid-sized for trials with a published cap, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Quartet 1457Q LV Lead is the first listed.
NCT02548455 names 20 study sites across 14 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT02548455 about?
NCT02548455 is a clinical study titled "Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study". The primary intent of this study is to assess the safety of the model 1457Q Quartet LV lead at 3 months in a patient population indicated for cardiac resynchronization therapy.
What is the current status of trial NCT02548455?
This trial is currently completed. It is a NA study. The enrollment target is 499 participants. The study started on 2015-10-27. Estimated completion is 2017-03-21.
What conditions does trial NCT02548455 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT02548455?
The interventions under investigation include: Quartet 1457Q LV Lead (DEVICE).
Who is sponsoring clinical trial NCT02548455?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02548455 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02548455's enrollment target sits among peer trials
499 105th of 397 higher than 293 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04137900 · 499 participants · Phase 1
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
- NCT06733480 · 499 participants · NA
Innovating Physical Therapy: A Pilot Study on Band Connect's Impact on Compliance, Satisfaction, and Revenue
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI